Association of Chronic Psoriasis with Syndrome X

Psoriasis and Metabolic Syndrome

Authors

  • Muhammad Faisal Bacha Department of Medicine, Akhtar Saeed Medical College, Rawalpindi, Pakistan
  • Muhammad Erfan Department of Medicine, Akhtar Saeed Medical College, Rawalpindi, Pakistan
  • Muhammad Noaman Department of Medicine, Akhtar Saeed Medical College, Rawalpindi, Pakistan
  • Tahir Mukhtar Sayed Department of Medicine, Akhtar Saeed Medical College, Rawalpindi, Pakistan
  • Jehanzaib Maqsood Department of Medicine, Akhtar Saeed Medical College, Rawalpindi, Pakistan
  • Wajahat Sultan Baig Department of Medicine, Wah Medical College, Rawalpindi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i7.1826

Keywords:

Cardiovascular Risk, Metabolic Syndrome, Psoriasis, Syndrome X

Abstract

Psoriasis is a chronic skin disorder and has been associated with a number of chronic inflammatory conditions. Syndrome X, which is commonly seen in our population and is responsible for major cardiovascular events, has been found to be linked with chronic skin disorders. Objective: To find out the link between Syndrome X and chronic plaque psoriasis in our population, to estimate the disease burden and plan the management strategies accordingly. Methods: This study included 130 participants selected through consecutive sampling including 65 patients as diagnosed cases of chronic plaque psoriasis and rest of 65 were controls. Data collection involved measuring body size, blood pressure, and lab investigations with lipids panel, complete blood counts and fasting sugar levels. For the diagnosis of Syndrome X, National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria was applied. Results: The study results revealed that Syndrome X was common in the psoriasis patients (41.5%) than the other group (23.1%) with a p value of 0.035. The majority of psoriasis patients were obese, had hypertension, sugar levels were elevated, higher triglycerides, and low HDL cholesterol. The bivariate analysis indicated that psoriasis was associated with the high tendency of developing syndrome X (p value of 0.021). Conclusion: The study findings highlighted that appropriate treatment of syndrome X in patients with chronic psoriasis can reduce the cardiovascular complications.

References

Saleem S, Imran Z, Samdani A, Khoso B, Zehra S, Azhar A. Mutations in PGRN gene associated with the risk of psoriasis in Pakistan: a case control study. BioMed Central Medical Genomics. 2023 Dec; 16(1): 335. doi: 10.1186/s12920-023-01757-8. DOI: https://doi.org/10.1186/s12920-023-01757-8

Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Frontiers in Medicine. 2021 Dec; 8: 743180. doi: 10.3389/fmed.2021.743180. DOI: https://doi.org/10.3389/fmed.2021.743180

Michalska A, Teichman R, Kręcisz B, Siudak Z, Stępień R, Sadowski M. Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020 Jun; 37(3): 299-305. doi: 10.5114/ada.2020.96085. DOI: https://doi.org/10.5114/ada.2020.96085

Fernández‐Armenteros JM, Gómez‐Arbonés X, Buti‐Soler M, Betriu‐Bars A, Sanmartin‐Novell V, Ortega‐Bravo M et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population‐based study. Journal of the European Academy of Dermatology and Venereology. 2019 Jan; 33(1): 128-35. doi: 10.1111/jdv.15159. DOI: https://doi.org/10.1111/jdv.15159

Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Frontiers in Medicine. 2015 Jan; 2: 1. doi: 10.3389/fmed.2015.00001. DOI: https://doi.org/10.3389/fmed.2015.00001

Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023 Jan; 37(1): 35. doi: 10.1007/s40259-022-00569-z. DOI: https://doi.org/10.1007/s40259-022-00569-z

Kiełbowski K, Bakinowska E, Bratborska AW, Pawlik A. The role of adipokines in the pathogenesis of psoriasis-a focus on resistin, omentin-1 and vaspin. Expert Opinion on Therapeutic Targets. 2024 Jul; 28(7): 587-600. doi: 10.1080/14728222.2024.2375373. DOI: https://doi.org/10.1080/14728222.2024.2375373

Ramos LM, Gomes KW, de Saboia Mont'Alverne AR, Braga MV, Vasconcelos AH, Rodrigues CE. High prevalence of metabolic syndrome in patients with psoriatic arthritis from Northeastern Brazil: association with traditional cardiovascular risk factors and biologic disease-modifying antirheumatic drugs. JCR: Journal of Clinical Rheumatology. 2021 Sep; 27(6S): S186-92. doi: 10.1097/RHU.0000000000001631. DOI: https://doi.org/10.1097/RHU.0000000000001631

Lee TH, Wu CH, Chen ML, Yip HT, Lee CI, Lee MS et al. Risk of psoriasis in patients with polycystic ovary syndrome: a national population-based cohort study. Journal of Clinical Medicine. 2020 Jun; 9(6): 1947. doi: 10.3390/jcm9061947. DOI: https://doi.org/10.3390/jcm9061947

Malik T, Nasreen S, Memon HS, Yousuf S, Khan S, Gul S. Association of Metabolic Syndrome and Psoriasis. Population. 2022 Jun; 6(4): 1104-1106. doi: 10.53350/pjmhs221641104. DOI: https://doi.org/10.53350/pjmhs221641104

Liu L, Cai XC, Sun XY, Zhou YQ, Jin MZ, Wang J et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. Journal of the European Academy of Dermatology and Venereology. 2022 Nov; 36(11): 1969-79. doi: 10.1111/jdv.18296. DOI: https://doi.org/10.1111/jdv.18296

Fabrazzo M, Romano F, Arrigo M, Puca RV, Fuschillo A, De Santis V et al. A multivariate analysis of depression prevalence in psoriasis patients: a cohort study. International Journal of Environmental Research and Public Health. 2022 Feb; 19(4): 2060. doi: 10.3390/ijerph19042060. DOI: https://doi.org/10.3390/ijerph19042060

Tariq J, Humaira M, Ahmed A, Memon A, Memon N, Shah M. Metabolic Syndrome in Obese and Non-Obese Individuals Presented at A Tertiary Care Hospital of Hyderabad, Pakistan: Metabolic Syndrome in Obese and Non-Obese Individuals. Pakistan Journal of Health Sciences. 2024 Nov: 226-30. doi: 10.54393/pjhs.v5i11.2549. DOI: https://doi.org/10.54393/pjhs.v5i11.2549

Arif A, Siddiqui S, Shafiq S, Rashid S, Aman S. Frequency of metabolic syndrome in patients of chronic plaque psoriasis. 2023 Jul.

Azhar M, Younas MT, Tahir M, Masud M, Tahir MZ, Tahir MZ. Prevalence of Metabolic Syndrome in patients with psoriasis. BioMed Central Journal of Medical Sciences. 2023 Dec; 4(2): 11-5. doi: 10.70905/bmcj.04.02.0149. DOI: https://doi.org/10.70905/bmcj.04.02.0149

Sabir, S., Ilyas, S., Khan, M., Imtiaz, H., & Khan, E. (2022). Frequency of Metabolic Syndrome in Patients with Chronic Plaque Psoriasis. Pakistan Journal of Medical & Health Sciences. 2022; 16(12): 256-256. doi: 10.53350/pjmhs20221612256. DOI: https://doi.org/10.53350/pjmhs20221612256

Ghias A, Khan MS, Shaheen E. Frequency of metabolic syndrome in patients of psoriasis. 2018 Jul.

Raza MH, Iftikhar N, Mashhood AA, Hamid MA, Rehman F, Tariq S. Frequency of metabolic syndrome in patients with psoriasis. Journal of Ayub Medical College Abbottabad. 2021 Jun; 33(3): 484-7.

Wang X, Wang L, Wen X, Zhang L, Jiang X, He G. Interleukin-18 and IL-18BP in inflammatory dermatological diseases. Frontiers in immunology. 2023 Jan; 14: 955369. doi: 10.3389/fimmu.2023.955369. DOI: https://doi.org/10.3389/fimmu.2023.955369

Rathod A, Neema S, Radhakrishnan S, Vendhan S, Tripathy DM, Vasudevan B. Palmoplantar Plaque Psoriasis is Associated with Diabetes, Hypertension, Obesity, and Metabolic Syndrome-A Case-Control Study. Indian Dermatology Online Journal. 2022 Sep; 13(5): 606-10. doi: 10.4103/idoj.idoj_59_22. DOI: https://doi.org/10.4103/idoj.idoj_59_22

Palmer V, Cornier MA, Waring A, Valdebran M. Evaluation and treatment of metabolic syndrome and cardiovascular disease in adult patients with psoriasis. International Journal of Dermatology. 2023 Dec; 62(12): 1437-46. doi: 10.1111/ijd.16873. DOI: https://doi.org/10.1111/ijd.16873

Rodríguez-Zúñiga MJ and García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology. 2017 Oct; 77(4): 657-66. doi: 10.1016/j.jaad.2017.04.1133. DOI: https://doi.org/10.1016/j.jaad.2017.04.1133

Hao Y, Zhu YJ, Zou S, Zhou P, Hu YW, Zhao QX et al. Metabolic syndrome and psoriasis: mechanisms and future directions. Frontiers in Immunology. 2021 Jul; 12: 711060. doi: 10.3389/fimmu.2021.711060. DOI: https://doi.org/10.3389/fimmu.2021.711060

Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y et al. Metabolic syndrome: updates on pathophysiology and management in 2021. International Journal of Molecular Sciences. 2022 Jan; 23(2): 786. doi: 10.3390/ijms23020786. DOI: https://doi.org/10.3390/ijms23020786

Al-Hamad D and Raman V. Metabolic syndrome in children and adolescents. Translational Pediatrics. 2017 Oct; 6(4): 397. doi: 10.21037/tp.2017.10.02. DOI: https://doi.org/10.21037/tp.2017.10.02

Downloads

Published

2025-07-31
CITATION
DOI: 10.54393/pjhs.v6i7.1826
Published: 2025-07-31

How to Cite

Bacha, M. F., Erfan, M., Noaman, M., Sayed, T. M., Maqsood, J., & Baig, W. S. (2025). Association of Chronic Psoriasis with Syndrome X: Psoriasis and Metabolic Syndrome. Pakistan Journal of Health Sciences, 6(7), 102–107. https://doi.org/10.54393/pjhs.v6i7.1826

Issue

Section

Original Article

Plaudit